drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous, genetically engineered T cells expressing a chimeric antigen receptor that targets CD19 on B cells to mediate cytotoxicity in relapsed/refractory diffuse large B-cell lymphoma.
nci_thesaurus_concept_id
C176018
nci_thesaurus_preferred_term
Anti-CD19 CAR T Cells Preparation
nci_thesaurus_definition
Any preparation of CAR-T cells that targets CD19.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express an anti-CD19 chimeric antigen receptor. CAR binding to CD19 on malignant and normal B cells triggers MHC-independent T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxicity, resulting in elimination of CD19-positive cells (e.g., in DLBCL).
drug_name
Anti-CD19 CAR T cells
nct_id_drug_ref
NCT06352242